859027-32-0

Basic information

• Product Name: 4-(4-nitro-2-trifluoromethyl-benzyl)-piperazine-1-carboxylic acid tert-butyl ester
• Synonyms: 4-(4-nitro-2-trifluoromethyl-benzyl)-piperazine-1-carboxylic acid tert-butyl ester
• CAS NO: 859027-32-0
• Molecular Weight: 389.375
• Mol File: 859027-32-0.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 4-(4-nitro-2-trifluoromethyl-benzyl)-piperazine-1-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-nitro-2-trifluoromethyl-benzyl)-piperazine-1-carboxylic acid tert-butyl ester(859027-32-0)
• EPA Substance Registry System: 4-(4-nitro-2-trifluoromethyl-benzyl)-piperazine-1-carboxylic acid tert-butyl ester(859027-32-0)

Safety Data

• Hazardous Substances Data: 859027-32-0(Hazardous Substances Data)

Upstream product

• 50551-17-2 4-nitro-2-(trifluoromethyl)benzaldehyde 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 89976-12-5 1-methyl-4-nitro-2-(trifluoromethyl) benzene 
• 694499-22-4 1-(bromomethyl)-4-nitro-2-(trifluoromethyl) benzene 

Downstream Products

• 859027-30-8 4-(4-amino-2-trifluoromethyl-benzyl)-piperazine-1-carboxylic acid tert-butyl ester 
• 943320-72-7 C₂₅H₂₉F₃IN₃O₃ 
• 1232836-37-1 3-iodo-4-methyl-N-[4-(piperazin-1-ylmethyl)-3-(trifluoromethyl)phenyl]benzamide 

Relevant articles and documents

PROTEIN DEGRADATION TARGETING COMPOUND, ANTI-TUMOR APPLICATION, INTERMEDIATE THEREOF AND USE OF INTERMEDIATE

The present disclosure relates to compounds of formula (I) and their anti-tumor uses, and their intermediates of formula (III), intermediates of formula (IV), and uses of the intermediates. The compound of formula (I) has a degrading effect on a specific target protein, which is mainly composed of three parts. The first part is a small molecule compound (SMBP, Small Molecules Binding Protein) that can bind to a protein, the second part LIN is a linker, and the three-part ULM is a ubiquitin ligand (ULM, Ubiquitin Ligase Binding Moiety), wherein SMBP is covalently bound to LIN, and LIN is covalently bound to ULM. A series of compounds designed and synthesized in the present disclosure have a wide range of pharmacological activities, including the functions of degrading specific proteins and/or inhibiting activities of specific proteins, and thus can be used in related tumor treatments.

BCR-ABL DIPLOID INHIBITOR, PREPARATION METHOD THEREFOR, AND USES THEREOF

Disclosed are compounds or pharmaceutically acceptable salts thereof having the following general formula: R-Linker-R. The compounds or pharmaceutically acceptable salts thereof provided by the present invention are used as Bcr-Abl diploid inhibitors, whi

Discovery of 3-[2-(imidazo[1,2- b ]pyridazin-3-yl)ethynyl]-4-methyl- N -{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant

In the treatment of chronic myeloid leukemia (CML) with BCR-ABL kinase inhibitors, the T315I gatekeeper mutant has emerged as resistant to all currently approved agents. This report describes the structure-guided design of a novel series of potent pan-inhibitors of BCR-ABL, including the T315I mutation. A key structural feature is the carbon-carbon triple bond linker which skirts the increased bulk of Ile315 side chain. Extensive SAR studies led to the discovery of development candidate 20g (AP24534), which inhibited the kinase activity of both native BCR-ABL and the T315I mutant with low nM IC 50s, and potently inhibited proliferation of corresponding Ba/F3-derived cell lines. Daily oral administration of 20g significantly prolonged survival of mice injected intravenously with BCR-ABLT315I expressing Ba/F3 cells. These data, coupled with a favorable ADME profile, support the potential of 20g to be an effective treatment for CML, including patients refractory to all currently approved therapies.